Immutep Limited has announced the discontinuation of TACTI-004, a pivotal Phase III clinical trial investigating eftilagimod alfa (efti) as a first-line treatment for advanced non-small cell lung cancer (NSCLC). According…
As reported on FiercePharma, China-based biotech Dizal Pharmaceutical has reported a pivotal phase 3 success for its oral EGFR inhibitor Zegfrovy (sunvozertinib), marking a potential shift in first-line treatment for…
Editor's Note: The following article was originally written by Kelly Curtin-Hallinan, and shared with us by our friends at Elephants & Tea. This past St. Patrick’s Day my daughter and…
Arexvy Now Available for Adults Aged 18–49 with Certain Health Conditions The U.S. Food and Drug Administration has granted approval to expand GSK's Arexvy respiratory syncytial virus (RSV) vaccine to…
As reported on PharmaBiz, the US Food and Drug Administration has broadened the approved use of GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, to include adults aged 18 to 49…
Editor's Note: The following in from author Stephen Policoff, whose book A Ribbon for Your Hair is out today! Introduction When Stephen Policoff’s adopted daughter Anna was four, a freak…
A New Solution to Address Critical Gaps in Glioma Diagnosis and Management Telix Pharmaceuticals, a biopharmaceutical company specializing in therapeutic and diagnostic radiopharmaceuticals, has taken a significant step forward in…
As reported on Healio, a novel biologic targeting two key angiogenic pathways has shown encouraging early results for the treatment of wet age-related macular degeneration (AMD). According to a recent…
Editor's Note: This story is a continuation of Jenny Decker's global sailing voyage. To see the original article, please click here. Many of our Patient Worthy readers are aware that…
AstraZeneca has received European Commission approval for Imfinzi (durvalumab) in combination with FLOT chemotherapy, a landmark achievement representing the first immunotherapy-based regimen to demonstrate survival benefits in early-stage gastric and…
People with rare and chronic disease often suffer from long term pain. New ways to alleviate this pain are needed. According to a press release from Tris Pharma, the results…
“Do not go gentle into that good night. Rage, rage against the dying of the light.” --Dylan Thomas One may have thought, after six months under constant supervision in a…
In a recent press release, Structure Therapeutics has reported encouraging topline results from its Phase 2 ACCESS clinical program evaluating aleniglipron, an investigational once-daily oral small-molecule glucagon-like peptide‑1 (GLP‑1) receptor…
As reported on Inside Precision Medicine, scientists in Germany have made an exciting discovery that could help children with a very rare and serious illness called Leigh syndrome (LS). This…
The biotechnology sector witnessed a striking demonstration of expedited drug development this week, with Boehringer Ingelheim receiving FDA approval for an innovative lung cancer therapy in less than two months,…
As reported by Pharma Times, Elevara Medicines has initiated a phase 2b clinical study evaluating ELV001, an investigational oral CDK4/6 inhibitor, in people with rheumatoid arthritis (RA) who continue to…
Pictured above: Giuliana Noratto, Ph.D., (left) and Lauren Stranahan, Ph.D., led research showing that compounds in dark sweet cherries may help slow the growth and spread of one of the…
Daiichi Sankyo has taken a significant step toward expanding treatment options in Japan by submitting regulatory approval for Enhertu, an advanced cancer-fighting drug designed to prevent recurrence in early-stage breast…
As reported by FiercePharma, the U.S. Food and Drug Administration has approved the first fully independent generic version of GlaxoSmithKline’s widely used asthma inhaler, Flovent, marking a significant shift in…
You can not see, hear, or touch my rare condition. I STINK! (LITERALLY) I wasn’t sure if I was going to tell my story. But I cannot forget a seventeen-year-old…
Researchers have created a fundamentally new class of HIV-fighting molecules by combining two separate antiviral mechanisms into a single engineered protein. Early laboratory results, reported by Forbes, suggest this integrated…
As reported on BioPharmaDive, UCB has reported positive results from a head-to-head clinical trial showing that its anti-inflammatory biologic Bimzelx was more effective than AbbVie’s Skyrizi in patients with active…
Editor's Note: Patient Worthy is proud and honored to share Jennifer's story with cystic fibrosis and colon cancer, originally published on the Cystic Fibrosis Research Institute's website. It started like…
The biotechnology sector experienced significant positive developments this week, with Xenon Pharmaceuticals' seizure medication achieving a decisive late-stage victory while regulatory pathways accelerated for several other promising therapies. According to…
As reported on Healio, glucagon-like peptide-1 (GLP-1) receptor agonists, best known for treating diabetes and obesity, are emerging as unexpected players in breast cancer care. Data presented at the recent…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
